Clinical Trial Update: A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating MK-0482 for relapsed or refractory acute myeloid leukemia and relapsed or refractory chronic myelomonocytic leukemia was terminated, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Acute Myeloid Leukemia
• Or Refractory Chronic Myelomonocytic Leukemia

Drugs mentioned

• MK-0482

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2024-12-11